REG - Abingdon Health PLC - Salistick™ to be launched in Tesco

Abingdon HealthAnnouncement

15/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230815:nRSO2745Ja&default-theme=true

RNS Number : 2745J  Abingdon Health PLC  15 August 2023

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Salistick™, the first ever saliva pregnancy test, to be launched in Tesco

 

York, U.K. 15 August 2023: Abingdon Health plc (AIM: ABDX), is pleased to
announce that Tesco will roll-out Salistick™, the first-ever saliva
pregnancy test, in 298 stores and online at Tesco.com from late-August 2023.

 

The launch of Salistick™ will be focused on larger Tesco stores as well as
online at Tesco.com. This follows the initial launch of Salistick™ with
Superdrug in 400 stores and online at Superdrug.com.

 

The Salistick™ pregnancy test offers women an improved user experience, with
high accuracy for early pregnancy detection. The revolutionary patented
technology allows saliva to be used as a sample rather than the traditional
urine sample. Salistick™ offers the ability to test anywhere, anytime, and
for the testing experience to be shared with a partner and other loved ones.
It is estimated that 12.5 million pregnancy tests were performed in the UK in
2022. The global pregnancy test kits market was valued at USD 1.70 billion in
2022 and is expected to reach USD 2.28 billion by 2028, growing at a CAGR of
5.08%((1)).

 

Abingdon Health is the exclusive distributor of Salistick™ in the UK and
Ireland on behalf of Salignostics Limited, an Israeli developer of innovative
saliva-based diagnostics tests. As well as providing distribution support
Abingdon Health has been providing Salignostics with contract development
services to scale-up the Salistick™ product for manufacture and will
continue to provide Salignostics with contract manufacturing services going
forward.

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to
announce the launch of Salistick™ with Tesco, online and rolled-out across
nearly 300 larger Tesco stores. This novel technology provides women with an
enhanced user-experience; offering the ability to test anywhere, anytime, and
for the testing experience to be shared with a partner and other loved ones.
We continue to explore distribution opportunities for Salistick™ both in the
UK and internationally and we look forward to launching the Salistick™ dual
pack in due course."

 

Sources:

1.     Pregnancy Test Kits Market Size, Share, Trends, Growth Forecast
(arizton.com)
(https://www.arizton.com/market-reports/pregnancy-test-kits-market)

 

Enquiries

 

 Abingdon Health plc                                              www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                             Via Walbrook PR
 Melanie Ross, Chief Financial Officer
 Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)       Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                  (mailto:abingdon@walbrookpr.com)
 Paul McManus / Phillip Marriage  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

 Alice Woodings                   +44 (0)7407 804 654

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format.  Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ecommerce site offers consumers a range of
information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of
this announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFEFILEDSEIA